Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 15/20 | 0.60 |
| ▸ | GAA | P10253 | 15/20 | 0.60 |
| ▸ | SI | P14410 | 15/20 | 0.60 |
| ▸ | MGAM2 | Q2M2H8 | 15/20 | 0.60 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CBFB | Q13951 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30166984 | 1.00 | MGAM (0.60) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL353891 | 0.79 | PARP1 (0.56) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL66295 | 0.79 | PSMB8 (0.59) | MGAMGAASIMGAM2NPC1 | |
| SCHEMBL1170892 | 0.79 | MGAM (0.71) | MGAMGAASIMGAM2ESR1 | |
| Bromide SCHEMBL5318091 | 0.78 | PARP1 (0.55) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL4352212 | 0.77 | MGAM (0.55) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL1192237 | 0.76 | NPC1 (0.50) | MGAMGAASIMGAM2NPC1 | |
| SCHEMBL6139625 | 0.76 | MGAM (0.60) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL4692683 | 0.76 | MGAM (0.53) | MGAMGAASIMGAM2ESR1 | |
| SCHEMBL110724 | 0.76 | MGAM (0.53) | MGAMGAASIMGAM2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174052-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174052-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170305929-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305929-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305929-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2016073407-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-12 | — | — | WO | disclosed |
| US-9212169-B2 | Benzimidazole derivative and use thereof | HYOGO COLLEGE OF MEDICINE (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212169-B2 | Benzimidazole derivative and use thereof | HYOGO COLLEGE OF MEDICINE (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212169-B2 | Benzimidazole derivative and use thereof | HYOGO COLLEGE OF MEDICINE (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150011600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | KAGOSHIMA UNIVERSITY (JP) | 2015-01-08 | — | — | US | disclosed |
| EP-0977740-A1 | METHODS FOR SYNTHESIZING 2-SUBSTITUTED IMIDAZOLES | SEPRACOR, INC. (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-2000005231-A1 | FKBP INHIBITORS | PFIZER LIMITED (GB) | 2000-02-03 | — | — | WO | disclosed |
| WO-1998046571-A1 | METHODS FOR SYNTHESIZING 2-SUBSTITUTED IMIDAZOLES | SEPRACOR INC. (US) | 1998-10-22 | — | — | WO | disclosed |
| US-5436240-A | Schizophrenia, Parkinson's disease, depression or hypotensive agents using tricyclic amines | THE UPJOHN COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0480939-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5273975-A | Heterocyclic amines having central nervous system activity | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| WO-1990015058-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-12-13 | — | — | WO | disclosed |
| EP-0209106-B1 | 2-(4-PYRIDYLAMINOMETHYL)-BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | Maruishi Seiyaku Kabushiki Kaisha (JP) | 1989-10-18 | — | — | EP | disclosed |
| US-4714764-A | ENTEROVIRUS AND RHINOVIRUS | MARUISHI SEIYAKU KABUSHIKI KAISHA (JP) | 1987-12-22 | — | — | US | disclosed |
| EP-0209106-A1 | 2-(4-Pyridylaminomethyl)-benzimidazole derivatives and pharmaceutical compositions | Maruishi Seiyaku Kabushiki Kaisha (JP) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174052-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | CHRNA7, CHRNA5, CHRNA2 | MGAM 4449/4885GAA 971/4885SI 2640/4885 |
| US-20150011600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | HDAC1, HDAC11, HDAC6 | MGAM 3834/4885GAA 473/4885SI 3361/4885 |
| US-20170305929-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA2 | MGAM 4410/4885GAA 920/4885SI 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.